Latest news
Summit Therapeutics Launches HARMONi-GU1 Trial for Ivonescimab in Bladder Cancer - The Clinical Trial VanguardThe Clinical Trial Vanguard · Thu, 06 Aug 2026 06:43:58 GMTSummit Therapeutics (NASDAQ: SMMT) launches Phase II/III HARMONi-GU1 bladder cancer study - Stock TitanStock Titan · Wed, 05 Aug 2026 11:32:48 GMTSummit Therapeutics Further Expands Ivonescimab Global Development Program with Phase II/III HARMONi-GU1 Study in 1L Bladder Cancer - Business WireBusiness Wire · Wed, 05 Aug 2026 11:00:00 GMTSummit Therapeutics (SMMT) Is Down 13.2% After Equity Offering And Ivonescimab Updates Has The Bull Case Changed? - webull.comwebull.com · Fri, 31 Jul 2026 21:27:19 GMTHARMONI@ELT: Instrument Design, Performance, And Science Capabilities - Astrobiology WebAstrobiology Web · Thu, 30 Jul 2026 17:38:16 GMT